As the first line of defense in the human immune system, NK cells play essential roles in prevention of tumorigenesis and viral infection. It is known that NK cells have impaired function in HIV infection; however, it remains unclear why this occurs. IP-10 is a chemokine and inflammatory factor that is associated with such diseases as tuberculosis, hepatitis B virus, and pancreatic cancer. The aim of this study was to evaluate IP-10 levels and CXCR3 expression in NK cells that were affected by HIV and to elucidate whether NK cell function could be affected by IP-10. Our results demonstrate that IP-10 levels and expression of CXCR3 in NK cells was significantly higher in HIV-infected participants compared with noninfected participants. Moreover, the ability of NK cells to secrete IFN-g and, specifically, to lyse K562, was suppressed with exposure to high levels of IP-10. This study also showed that CXCR3 + NK cell function decreased dramatically when treated with IP-10, which indicates that CXCR3 + NK cells were the main targets of IP-10. Furthermore, IP-10 or CXCR3 blocking could restore NK cell function. These data suggest that elevated IP-10 levels may impair NK cell function during HIV infection and that IP-10/CXCR3 blocking may be a novel therapeutic strategy in the control and functional cure of HIV.
Introduction
NK cells are critically important immunocytes in the control of viral infections and are widely known as the first line of defense of the human immune system [1] . Immediate release of such cytokines as IFN-g, perforin, and granzyme by NK cells in the early stages of infection is crucial for inducing virus-specific immunity [2] . Four subsets of NK cells can be defined by their differential expression of CD56 and CD16. These are composed of cytolytic CD56 dim CD16 + NK cells, which is the largest population of NK cells, cytokine-and chemokine-secreting CD56 bright CD16 +/2 NK cells, CD56 dim CD16 2 NK cells [3] , and CD56 2 CD16 + NK cells, which have recently been shown to expand during persistent HIV viremia [4] . Chronic HIV infection can dramatically damage innate and adaptive immunity. As a major component of innate immunity, NK cells have been the subject of several studies that have demonstrated the functional impairment of NK cells in HIV infection. Such impairment includes changes in cytokine secretion and surface expression of natural cytotoxic and activating receptors [5] [6] [7] . In addition, significant changes in the NK cell compartment, such as a decline in the proportion of CD56 dim CD16 + NK cells and an expansion of CD56 2 CD16 + NK cells, have been observed [8] . IP-10 is a 10-kDa IFN-g-induced protein and also known as CXCL10 [9, 10] . The biologic function of IP-10 is to induce chemotaxis, cell growth, angiostasis, and apoptosis via binding its receptor, CXCR3, a 7 transmembrane-spanning G proteincoupled receptor [11] . In addition, IP-10 has been reported to be associated with a variety of diseases, such as tuberculosis [12, 13] , hepatitis B virus [14, 15] , and pancreatic cancer [16] . Recently, studies have shown that IP-10 also plays a role in HIV infection. Stylianou et al. [17] demonstrated persistently high levels of CXCL10 associated with immunologic treatment failure after ART in HIV-infected patients. Significantly lower expression of IP-10 in HIV-exposed seronegative sex workers has been associated with protection of the mucosal immune system [18] . Ramirez et al. [19] found that IP-10 levels were not only significantly higher in untreated HIV-infected patients, but were also higher in HIV-infected patients receiving ART. Ramirez et al. also demonstrated that high plasma levels of IP-10 suppress T cell function in HIV-infected participants. The effect that high levels of IP-10 has on NK cells-a major component of innate immunity-during HIV infection is unknown.
To our knowledge, this study is the first to investigate the effect of IP-10 on NK cell function during HIV infection. These data show that IP-10 can suppress NK cell function, both IFN-g secretion and the specific lysis of K562. We also show that NK cells express significantly higher CXCR3 in HIV-positive participants. In addition, our study found that NK cell function could be restored after blocking IP-10 or CXCR3, which suggests a new therapeutic strategy for functional cure of HIV using the augmentation of immune cell function.
MATERIALS AND METHODS

Study participants
All participants gave written informed consent, and the study was evaluated and accepted by the Research and Ethics Committee of The First Affiliated Hospital of China Medical University (Shenyang, China) and conducted according to the Declaration of Helsinki principles. The study population included HIV-negative participants with no apparent active infections who were also negative for hepatitis B and hepatitis C virus, HIV + participants who had never been treated with ART and were infected for 1-5 yr, and HIV + participants who had been receiving treatment with ART for .1 yr with undetected viral loads. None of the HIV-infected participants had apparent active opportunistic infections at the time of the study.
Measurement of plasma cytokine/chemokine profiles
A Bio-Plex Pro Human Cytokine Assay (Bio-Rad, Hercules, CA, USA) was used to examine plasma from 20 untreated HIV-infected participants, 30 HIVinfected participants receiving ART, and 20 HIV-negative participants. Each sample was assayed in duplicate, and the cytokine standards supplied by the manufacturer were run on each plate. Data were acquired using a Bio-Plex 200 (Bio-Rad) and were analyzed using Bio-Plex Manager software (v4.1; Bio-Rad).
NK cell IFN-g secretion and CD107a expression assays
To measure NK cell function in HIV infection, PBMCs from HIV + , HIV + participants on ART, and HIV-negative participants were stimulated with 10 ng/ml IL-12 (R&D Systems, Minneapolis, MN, USA) and 50 ng/ml IL-15 (R&D Systems) for 24 h. IFN-g (APC) secretion and CD107a (PE) expression was measured by flow cytometry assay. To investigate NK cell function with IP-10 treatment (R&D Systems), different concentrations of IP-10 (0 ng/ml, 500 pg/ml, and 5 and 100 ng/ml) were used. PBMCs from HIV-negative participants were used, and, with the exception of the unstimulated group, each group was treated with IP-10 and stimulated with 10 ng/ml IL-12 and 50 ng/ml IL-15 for 24 h. During the last 6 h of the 24-h period, GolgiStop (BD Biosciences, San Jose, CA, USA) was added, and the frequency of IFN-g + NK was measured by flow cytometry assay.
NK killing K562 assays
In specific lysis assays, NK cells were cocultured with K562 in a 5:1 E:T ratio for 6 h and analyzed via flow cytometry assay. K562 had been previously labeled with CFSE, and 7-AAD (BD Biosciences) was used to assess the frequency of killed K562. The frequency of specific lysis was calculated as follows: frequency = (killed K562 2 natural death K562)/total K562.
IP-10 blocking assays
To investigate NK cell function after IP-10 was blocked, 200 ng/ml human IP-10 mAb (R&D Systems) and 500 pg/ml CXCR3 antagonist (Tocris Bioscience, Bristol, United Kingdom) were used. PBMCs were from HIV-negative participants, and, with the exception of the unstimulated group, each group was treated with 5 ng/ml IP-10 and stimulated with 10 ng/ml IL-12 and 50 ng/ml IL-15 for 24 h. During the last 6 h of the 24-h period, GolgiStop was added and the frequency of IFN-g + NK was measured by flow cytometry assay.
Flow cytometry analysis
NK cells were analyzed from freshly isolated PBMCs using an LSR II Fortessa cytometer (BD Biosciences) that was calibrated for use with 8-peak color rainbow beads (Spherotech, Lake Forest, IL, USA). Three separate staining panels were used: 1) NK function: CD3-PerCP-Cy5. 
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6.0 software (GraphPad Software, La Jolla, CA, USA). The nonparametric Mann-Whitney U test was used to compare between-group distribution with a significance threshold set at P , 0.05. Wilcoxon matched pairs test was used for paired comparisons.
RESULTS
High IP-10 levels suppress NK cell IFN-g secretion and the specific lysis of K562
We assessed IP-10 levels in 70 participants and found significant differences in IP-10 levels between HIV + participants who had been infected 1-5 yr, HIV + participants receiving ART for .1 yr with undetectable viremia, and NC participants (Fig. 1A) . IP-10 levels were significantly higher in HIV + participants (2832.88 6 1468.83 pg/ml) compared with NC participants (1430.60 6 463.04 pg/ml; P = 0.0002) and those with HIV + receiving ART (1984.16 6 896.95 pg/ml; P = 0.0113). IP-10 is an important chemokine related to inflammation, and significantly high IP-10 levels in humans might impact crucial components of innate immunity, such as NK cells. The impact of high levels of IP-10 on NK cell function was examined in this study. Results demonstrate that secretion of IFN-g by NK cells from NC participants was significantly decreased in NK cells that were treated with 5 or 100 ng/ml IP-10 compared with that from NK cells that were treated with 0 ng/ml IP-10 (P = 0.0052 and P = 0.0115, respectively; Fig. 1C and D) . Furthermore, we investigated the effect of 5 ng/ml IP-10 on NK cells from HIV + individuals, and results show that IP-10 also suppressed NK cell function in HIV infection (Fig. 1E) . Moreover, this study found that IP-10 could suppress the specific lysis of K562 (P = 0.013; Fig.  1F and G). These results demonstrate that higher levels of plasma IP-10 exist in HIV-infected participants, and the function of NK cells was damaged with IP-10 treatment in both NC or HIV + participants.
Elevated CXCR3 expression on NK cells in HIV infection
High levels of IP-10 may influence the function of NK cells via its receptor. Assessment was performed of CXCR3 expression on total NK cells and 4 NK cell subsets from HIV + participants, HIV + participants receiving ART, and NC participants (Fig. 2) . Flow cytometry data revealed that the amount of CXCR3 + NK cells was not only significantly higher in HIV + participants, but also in HIV + participants receiving ART participants ( Fig. 2A) CXCR3 receptor includes 2 major variants (CXCR3A and CXCR3B) that cannot be identified by flow cytometry at present because no separate Ab was available. We detected the mRNA of the 2 variants and data showed that CXCR3-A was significantly higher in HIV + participants compared with NC participants, and that CXCR3-A was much higher than CXCR3-B only in HIV + participants; however, there was no significant difference between CXCR3-A and CXCR3-B mRNA expression in NC and HIV + participants receiving ART (Supplemental Fig. 1 ).
IP-10 mainly suppresses the function of CXCR3 + but not CXCR3
2 NK cells expression were decreased in CXCR3 + NK cells that were treated with 5 ng/ml IP-10 ( Fig. 3B and D) , but IP-10 had no effect on CXCR3 2 NK cell function ( Fig. 3C and E in HIV + participants (Fig. 3F) in HIV + participants (n = 5), HIV + participants receiving ART (n = 5), and NCs (n = 7). Graphs represent median 6 interquartile range. **P , 0.01, Mann-Whitney U test comparing median between groups.
Blocking IP-10 or CXCR3 receptor restores NK cell function
As NK cell function was suppressed by IP-10, our study examined whether NK cell function could be enhanced using IP-10 mAb or CXCR3 antagonist. The proportion of IFN-g secretion by NK cells that were treated with IP-10 mAb or CXCR3 antagonist was examined (Fig. 4A) . There was significant enhancement in IFN-g secretion after cells were treated with 2 mg/ml IP-10 mAb for 24 h. Furthermore, 500 pg/ml CXCR3 antagonist was administered for 24 h and showed a blockade of the suppression by IP-10 on NK cell function (Fig. 4B) . We further evaluated the IP-10 mAb or CXCR3 antagonist effect on NK cells from HIV + participants.
Results show that NK cell function was significantly increased after IP-10 blocked was by 2 mg/ml IP-10 mAb (P = 0.0313). No significant restoration of the NK cell function blocked with 500 pg/ml CXCR3 antagonist (P = 0.098) in HIV + participants has been found; however, increased trends of NK cell function could be observed after being treated with CXCR3 antagonist (Fig. 4C) . CXCR3 antagonist alone and mouse IgG1 isotype control for IP-10 mAb, which were used as controls, played no effect on NK cell function (Supplemental Figs. 2 and 3) . In a word, blocking of IP-10 or CXCR3 restored NK function in both in NC and in HIV participants, which provides novel insight into immune reconstruction of HIV infection.
DISCUSSION
NK cells play a crucial role in fighting HIV infection; however, NK cell function is damaged by HIV infection. Why NK cell function is impaired in HIV remains to be understood. Previous studies have demonstrated that alterations in IP-10 levels have been associated with inflammatory diseases, including immune dysfunction, infectious diseases [20] [21] [22] , and neoplasm development [16] . IP-10 is also recognized as a biomarker that predicts the severity of various diseases [9, [23] [24] [25] . It was reported that in HIV infection, IP-10 is shown to be the only cytokine-among the 26 tested-that was significantly increased during the early stage of disease [26] , and IP-10 levels have been associated with immune activation, low CD4 + T cell counts [27] , and decreased T cell function [19] . Indeed, T cells play key roles in disease progression and prognosis in HIV infection; however, attention must also be paid to NK cells, which act as the first line of defense in the innate immune system. NK cell dysfunction may contribute to rapid disease progression and changes in CD4 + T cell counts. To our knowledge, this is the first study to demonstrate that significantly increased IP-10 levels can lead to the suppression of NK cell function, including both IFN-g secretion and CD107a expression. Moreover, IP-10 mainly suppressed the function of CXCR3 + NK cells. In NCs, we found that the biologic function of CXCR3 + NK cells was more robust than CXCR3 2 NK cells, whereas in HIV + participants, CXCR3 + NK cells had much lower IFN-g secretion than did NCs. Collectively, these results show that IP-10 suppressed the function of NK cells mainly via binding to its receptor, CXCR3. Further details of this mechanism are unknown. Ramirez et al. [19] found that IP-10 suppresses T cell function, that transcription of the p38 molecule in the downstream signaling pathway of CXCR3 in T cells has been reported to be reduced, and that calcium response has been shown to be lower in the presence of high levels of IP-10. Suppression of NK cell function by IP-10 might be explained by a similar mechanism. In addition, IP-10 levels are much higher during acute HIV infection [26] , and our data show that NK cell function could be suppressed within 24 h, which means that human innate immunity cannot play its expected role in the early stage of infection. As such, NK cells cannot control viral infection, and disease progression and viral set points are impacted.
To our knowledge, this study is the first to propose that IP-10 suppresses NK cell function via CXCR3, and HIV infection could increase CXCR3 expression of NK cells. We tested CXCR3 expression in 4 NK cell subsets and found that the CD56 dim CD16 + subset had higher CXCR3 expression in HIV + participants. The main function of the CD56 dim CD16 + subset is killing. We deduced that significantly increased CXCR3 expression in this subset might decrease NK cell function in controlling HIV transmission. Moreover, our study also confirmed that the CD56 2 CD16 + subset had increased CXCR3 expression during HIV infection, and, as CD56 2 CD16 + is known to be the subset that is elevated in HIV infection and showed no cytotoxicity, increased CXCR3 expression may provide a reasonable explanation for this dysfunction. It has been shown that IP-10 binding CXCR3 leads to the impairment of NK cells, and this may provide a new explanation for NK cell dysfunction in HIV infection, especially in CD56 2 CD16 + NK cells. This study also showed that CD56 bright CD16 +/2 NK cells had the highest CXCR3 expression among the 4 NK cell subsets. Although there is no significant increase of CXCR3 expression in these cells in HIV infection, we deduced that high IP-10 could still impair the function of this NK cell subset. Three variants of CXCR3 (CXCR3-A, CXCR3-B, and CXCR3-alt) have been identified in human cells. Many researchers have focused on the role of the 2 major CXCR3 isoforms (CXCR3-A and CXCR3-B) in cancer progression and have found that these variants may exert different-even opposite-functions in cancer. CXCR3-A was reported overwhelmingly to be expressed on leukocytes and CXCR3-B on endothelial cells and fibroblasts [28] . In prostate cancer cells, the CXCR3A mRNA level was up-regulated, whereas CXCR3-B mRNA was down-regulated, which promoted tumor metastasis via stimulation of cell migration and invasion [29] -the same result was also demonstrated in clear cell ovarian cancer [30] . Meanwhile, in gastric cancer, up-regulation of CXCR3-B correlates with the favorable prognosis of patients with gastric cancer [31] ; however, the effect of CXCR3-A and CXCR3-B on NK cells was still unknown. To identify which CXCR3 variants are elevated in NK cells, we first measured the mRNA levels of CXCR3-A and CXCR3-B. These data show that the CXCR3-A mRNA expression of HIV + participants was significant higher than that in NCs, which is consistent with the flow cytometry results that show elevated CXCR3 expression in HIV + participants. Therefore, high levels of IP-10 might combine with CXCR3-A receptor and lead to the impairment of NK function, a mechanism that should be further elucidated in future studies. In this study, NK cell function that was suppressed by IP-10 was restored by using IP-10 mAb in NCs and HIV + participants, whereas CXCR3 antagonist restored NK cell function of NC participants, and there was an elevated trend in HIV + participants. We deduced that as CXCR3 expression of NK cells was elevated in HIV + participants, the same dose of CXCR3 antagonist for NC participants was not enough to completely block the CXCR3 receptor in HIV + participants, and a larger dose might have a better effect. IP-10 inhibitor has already been used as treatment for such diseases as moderate-to-severe active ulcerative colitis [32] , influenza A (H1N1) virus-induced acute lung injury [33] , virus-induced asthma [34] , and intestinal inflammation [35] . Our findings reveal that NK cell function and CXCR3 expression were changed as a result of elevated IP-10, which provides a novel explanation for impaired NK cell function in HIV infection.
Our data indicate that blocking IP-10 or CXCR3 might be a future immune strategy for a functional cure of HIV infection. First, HIV-infected individuals should be treated with ART to decrease the viral load and to restore host immune function. Then, at the proper time, ART could be stopped and IP-10 inhibitors administered to protect the function of NK and T cells. After the immune system controls the virus, IP-10 inhibitors could then be removed, possibly achieving functional cure. AUTHORSHIP Z.W., Y.J., and H.S. designed the study and wrote and edited most of the drafts of the article. Z.W., T.W., and M.M. performed the experiments. Z.Z., Y.F., and X.H. contributed reagents and materials. Y.W. provided additional advices for the design of experiments. J.L., J.X., H.D., and Z.C. provided samples for this study. All authors provided feedback to the writing of the article and approved the final version.
